Advertisement

Topics

PhoreMost Company Profile

03:52 EDT 23rd October 2018 | BioPortfolio


News Articles [18 Associated News Articles listed on BioPortfolio]

With $15m raised, PhoreMost ‘ready for more collaborations’

The UK-based biopharmaceutical company PhoreMost has completed a Â11m ($15m) Series-A investment round, preparing the company for âmore collaborationsâ later this year, says CEO.

PhoreMost gets £11mm in Series A round

UK drug discovery start-up PhoreMost Ltd. raised £11mm ($15mm) in its Series A financing led by returning shareholders Jonathan Milner, Amadeus Capital Partners, Cambridge Enterprise, and Parkwalk Ad...

PhoreMost completes $15M Series-A round to enter drug discovery

PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has completed an £11m ($15m) Series-A investment round. The investment wi...

PhoreMost and Plexxikon Collaborate to Identify Novel Drug Targets

PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon I...

PhoreMost, NeoPhore secure Innovate UK funding for small-molecule cancer immunotherapy program

PhoreMost and NeoPhore are set to receiv £1m of funding to develop a novel small-molecule cancer immunotherapy program following award of a Biomedical Catalyst grant in a recent Innovate UK competiti...

PhoreMost and o2h discovery collaborate to progress first-in-class drug discovery programs

PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has entered into a collaboration with o2h discovery (...

PhoreMost and o2h discovery collaborate to progress first-in-class drug discovery programs.

Cambridge, UK, 21 June 2018: PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has entered into a collaboration...

PhoreMost Ltd and Plexxikon collaborate to identify novel drug targets

Cambridge, UK, 16 April 2018: PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agre...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

More Information about "PhoreMost" on BioPortfolio

We have published hundreds of PhoreMost news stories on BioPortfolio along with dozens of PhoreMost Clinical Trials and PubMed Articles about PhoreMost for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of PhoreMost Companies in our database. You can also find out about relevant PhoreMost Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record